Streetbeat News

Products Services

HDRO

HYDR

PLUG

Plug Power, Inc. (NASDAQ:PLUG) shares are trading lower by 13.4% to $2.52 premarket on Friday. The company announced the pricing of its public offering of 78.74 million shares at $2.54 per share, with an option for underwriters to purchase an additional 11.81 million shares. The offering is expected to close around July 22, 2024, and aims to raise approximately $200 million for general corporate purposes. Plug Power has also completed the deployment of 13 hydrogen refueling stations across Europe over the past two years.

Portfolio Pulse from Nabaparna Bhattacharya

July 19, 2024 | 12:43 pm

CRWD

MSFT

Mount Sinai Health System is experiencing a third-party software outage affecting its computer systems. The affected systems have been identified and isolated, and the technology team is working to remediate and restore them.

Portfolio Pulse from Benzinga Newsdesk

July 19, 2024 | 12:43 pm

BTI

The FDA has granted marketing orders to R.J. Reynolds Vapor Company, a subsidiary of British American Tobacco (NYSE: BTI), for its Vuse Alto Power Unit and six tobacco-flavored pods. This decision follows an extensive scientific review and is aimed at protecting public health by providing a potentially safer alternative for adult smokers. However, the FDA has imposed stringent marketing restrictions to mitigate youth use. BTI shares are trading slightly higher in premarket trading.

Portfolio Pulse from Shivani Kumaresan

July 19, 2024 | 12:37 pm

F

FDIS

RIVN

TSLA

XLY

Tesla Inc. (NASDAQ:TSLA) saw a 24% drop in car registrations in California in Q2, marking the third consecutive quarter of decline. Increased competition and high interest rates are driving consumers towards hybrid vehicles. CEO Elon Musk's controversial public persona is also affecting Tesla's brand. Competitors like Hyundai, Kia, BMW, Mercedes-Benz, Ford, and Rivian saw sales increases. Tesla's stock has lost over 14% in the last 12 months, but shares are trading slightly higher in premarket.

Portfolio Pulse from Shivani Kumaresan

July 19, 2024 | 12:36 pm

SXTP

60 Degrees Pharmaceuticals shares are trading higher after the company signed clinical trial agreements with three planned trial sites for the Tafenoquine Babesiosis study.

Portfolio Pulse from Benzinga Newsdesk

July 19, 2024 | 12:36 pm

PALI

Palisade Bio shares are trading higher following the announcement that the European Patent Office has granted a patent for their Gut Microbiota Bioactivated PDE4 Inhibitor Precursors.

Portfolio Pulse from Benzinga Newsdesk

July 19, 2024 | 12:33 pm

PALI

Palisade Bio has announced that the European Patent Office has issued a decision to grant a patent for 'Gut Microbiota Bioactivated PDE4 Inhibitor Precursors,' covering their PALI-2108 and PALI-1908 programs. This patent provides Composition of Matter coverage until beyond 2042. PALI-2108 is being developed for Ulcerative Colitis, and PALI-1908 for Crohn's Disease.

Portfolio Pulse from Benzinga Newsdesk

July 19, 2024 | 12:32 pm

BDRX

Biodexa Pharmaceuticals has announced the pricing of a $5 million registered direct offering and a concurrent private placement. The company will sell 5,050,808 American Depositary Shares and 278,975 pre-funded warrants. The proceeds will be used to fund development programs, including a $17 million CPRIT grant match and a Phase 3 eRapa trial in Familial Adenomatous Polyposis, as well as for working capital and general corporate purposes.

Portfolio Pulse from Benzinga Newsdesk

July 19, 2024 | 12:32 pm

FSLR

First Solar has announced ownership of patents for manufacturing Tunnel Oxide Passivated Contact (TOPCon) c-Si PV solar cells, secured through its 2013 acquisition of TetraSun. The patents are issued in multiple countries and are valid through 2030. First Solar is evaluating options and investigating potential infringements.

Portfolio Pulse from Benzinga Newsdesk

July 19, 2024 | 12:30 pm

SXTP

60 Degrees Pharmaceuticals has signed clinical trial agreements with Yale University, Rhode Island Hospital, and Tufts Medical Center for a study on Tafenoquine for Babesiosis. Patient enrollment has begun, with interim results expected by September 2025. The market for ARAKODA® (tafenoquine) for babesiosis is approximately 400,000 patients in the U.S.

Portfolio Pulse from Benzinga Newsdesk

July 19, 2024 | 12:30 pm